跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2019-003317-33-NL
EUCTR2019-003317-33-NL进行中（未招募）1 期

A first-in-human, open-label, dose escalation followed by dose expansion phase I/IIa trial to evaluate the safety, preliminary efficacy and pharmacokinetics of intratumoral CyPep-1 monotherapy and in combination with pembrolizumab in patients with advanced solid cancers. - CICILIA

Cytovation ASA0 个研究点目标入组 84 人开始时间: 2019年10月9日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
84
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •MAIN Criteria: Limited characters
  • •Phase I and Phase IIa Arms A and C:
  • •1. Histologically or cytologically confirmed locally advanced (unresectable) or metastatic tumors (solid tumor or lymphoma) with an accessible tumor lesion for intratumoral injection of CyPep-1 malignancy that is either refractory to standard-of-care treatment or have a disease for which there is no standard therapy considered appropriate.
  • •2.1-3 non-ulcerated transcutaneously accessible lesion(s) for injection and measurable as defined by iRECIST.
  • •3. Presence of tumor lesion(s) (that have not been previously irradiated) suitable for biopsy at screening and at Week 6.
  • •4.Confirmation of the presence of at least 1 liver metastasis by imaging.
  • •5.Subjects must have measurable disease which is equal to one or more metastatic liver lesions that can be accurately and serially measured that are greater than 1 cm dimension and for which the longest diameter is = 1 cm as measured by CT scan or MRI.
  • •6.Metastatic liver lesion for injection with >50% radiological visible necrosis must be avoided and the lesion must be located where any tumor swelling will not lead to gall bladder tract obstruction or bleeding risk.
  • •7. Histologically or cytologically confirmed diagnosis of advanced (unresectable Stage III) or metastatic (Stage IV: M1a and/or M1b) melanoma considered incurable.
  • •8. Previously exposed to ICI(s) and be categorized following the SITC Immunotherapy Resistance Taskforce meeting one of criteria listed in protocol
  • •9. At least 1 non-ulcerated lesion, not exceeding 5 cm in (the longest) diameter, for intratumoral injection(s) and measurable as defined by iRECIST.
  • •10. Resolution of toxicity due to prior therapy returned to baseline or < Grade 2, except for alopecia or other irreversible immune-mediated AEs, as defined by CTCAE v5.0. and SITC ICI-related AEs.
  • •11.Prior treatment(s) delivered by IT injection to the to-be injected lesion(s), including investigational agents, is allowed.
  • •Phase I and Phase IIa Arms A, C and D in addition:
  • •12.Age = 18 years.
  • •13.Estimated life expectancy of at least 3 months.
  • •14.Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • •15.Resolution of toxicity due to prior therapy to Grade < 2 (except for alopecia and transaminases in case of liver metastases) as defined by CTCAE v5.0.
  • •16.Ability to give written informed consent and to comply with the protocol.
  • •17.WOCBP must have a negative highly sensitive pregnancy test at screening and agree to use highly effective method for contraception at least 120 days after the last administration of CyPep-1. The partners of WOCBP must also apply contraceptive methods and are recommended not to donate sperm.
  • •18. A male participant must agree to use contraception and refrain from sperm donation during the treatment period and for at least 120 days after the last dose of trial medication.
  • •19.Adequate bone marrow, liver, and renal function
  • •For Phase IIa Arm B:
  • •20.The participant provides written informed consent for the trial.
  • •21.Age =18 years
  • •22.Histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumor malignancy that is refractory to SoC treatment or for which there is no appropriate standard therapy. Metastatic deposits of tumors for which IT injections may be performed are eligible. Pure cutaneous infiltrations are ineligible.
  • •23.Subjects must have progressed on treatment with an anti-PD1/L1 monoclonal antibody (mAb) administ

排除标准

  • •MAIN Criteria: Limited char.
  • •Phase I and Phase IIa Arm A, C and D:
  • •1.prior treatment(s) with compounds delivered by IT injection to the to-be injected lesion(s), including investigational agents. Subjects with prior IT therapies are allowed in Arm D.
  • •2.Participation in another clinical trial within 4 weeks prior to first dose of CyPep-1.
  • •3.Anti-cancer therapy within 4 weeks prior to the first dose of CyPep-1
  • •4.Major surgical procedure within 14 days prior to the first dose of CyPep-1.
  • •5.Live vaccine within 30 days prior to first dose of CyPep-1.
  • •6.Expected to require any other form of systemic or localized antineoplastic therapy while in this trial.
  • •7.Clinical evidence of an active second malignancy that is progressing or requires active treatment, except for curatively treated early stage carcinomas or non-melanoma skin cancer.
  • •8.Active autoimmune disease requiring immunosuppressive therapy.
  • •9.Any condition requiring continuous systemic treatment with either corticosteroids
  • •or other immunosuppressive agents within 2 weeks prior to first dose of CyPep-1.
  • •10.Abnormal or clinically significant coagulation parameters: PT-INR + APTT
  • •11.Subjects on anticoagulants with temporarily stop and start, supported by low molecular weight heparin (or other anticoagulation therapy) during treatment period.
  • •12.Known hypersensitivity to any component of CyPep-1.
  • •13.Prior allogeneic tissue/solid organ transplant, stem cell or bone marrow transplant.
  • •14.Known active human immunodeficiency virus (HIV). Subject is eligible when normal levels of CD4 are present.
  • •15.Central nervous system metastasis that is symptomatic or progressing or that requires current therapy
  • •16.QTcF > 480 ms, history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation, or Torsade de Pointes.
  • •17.Women who are pregnant or breastfeeding.
  • •18.Any serious and/or unstable pre-existing medical, psychiatric or other condition which in the investigator’s opinion could interfere with subject safety, obtaining written informed consent, or compliance with the trial protocol.
  • •19. Has an active acute or chronic infection requiring systemic therapy at the time of CyPep-1 injection.
  • •Additional for Phase IIa Arm C:
  • •20.Subject is a candidate for hepatic surgery or local regional therapy of liver metastases with curative intent.
  • •21.More than 1/3 of the liver is estimated to be involved with metastases.
  • •22.There is invasion by cancer into the main blood vessels.
  • •23.Subject is currently receiving or has received liver metastatic-directed therapy less than 4 weeks prior to enrolmentor hepatic surgery.
  • •Phase IIa Arm B:
  • •Some criteria for arm B correspond to criteria for Phase I and Arm A and C. Due to the character limitation only a reference to these sections is listed below.
  • •25.Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a Grade 3 or higher irAE.
  • •26.Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks (within 1 week for endocrine therapy) prior to first dose of CyPep-1.
  • •27.Has received prior (palliative) radiotherapy within 2 weeks of start of trial treatment.
  • •31.Ongoing pembrolizumab-related toxicity event(s) as per TLT definition.
  • •33.Has had an allogeneic tissue/solid organ transplant.

研究者

相似试验

进行中（未招募）
1 期
A first-in-human, open-label, dose escalation followed by dose expansion phase I/IIa trial to evaluate the safety, preliminary efficacy and pharmacokinetics of intratumoral CyPep-1 monotherapy and in combination with pembrolizumab in patients with advanced solid cancers. - CICILIASubjects with incurable advanced or metastatic solid tumor malignancy for whom no treatment options exist and who have tumor lesion that is accessible for intratumoral injection of CyPep-1.
EUCTR2019-003317-33-ESCytovation AS45
招募中
不适用
A first-in-human, open-label, dose escalation followed by dose expansion phase I/IIa trial to evaluate the safety, preliminary efficacy and pharmacokinetics of intratumoral CyPep-1 monotherapy and in combination with pembrolizumab in patients with advanced solid cancers.Solid malignant tumors10027656
NL-OMON54523Cytovation ASA65
进行中（未招募）
1 期
First in Human Testing of Dose-escalation of SAR440234 in Patients with Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome
EUCTR2017-004148-39-FRSanofi-Aventis Recherche & Développement77
进行中（未招募）
1 期
First-in-human study of ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas.
EUCTR2016-004484-39-GBBayer AG910
进行中（未招募）
1 期
First-in-human study of ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas.Part A: Histologically confirmed solid tumors and lymphomas, J-arm : Advanced solid tumorsPart B: a) DDR defects putative biomarker-positive advanced solid tumors: i) CRPCii) lung cancer, including adenocarcinoma, squamous carcinoma, or small cell lung canceriii) colorectal canceriv) gynecological tumors. b) Advanced mantle cell lymphoma. Diffuse large B cell lymphoma. Part C: CRPC with symptomatic confirmed bone metastases and no known visceral metastatic disease.MedDRA version: 20.0Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2016-004484-39-FRBayer AG320